Australia Health

Melbourne-based Nexalis Therapeutics (ASX:NX1) has enrolled the first participant in its Phase 1 clinical trial for IRX-616a.

Entropy Neurodynamics (ASX:ENP) announced a milestone in its clinical trial investigating TRP-8803 for the treatment of binge eating disorder.

Avecho Biotechnology (ASX:AVE) completed patient recruitment for Phase 3 insomnia trial interim analysis.

PYC Therapeutics (ASX:PYC) confirmed that it has received approval from its Safety Review Committee to escalate dosing in its PYC-003 drug candidate trial.

ECS Botanics (ASX:ECS) delivered both a return to profitability and positive cash flow for the first half of FY26.

Mach7 Technologies (ASX:M7T) reported total revenue of $13.7 million for H1 FY26, representing a 23% decline a year earlier.

Mesoblast (ASX:MSB) logged total revenue surged to US$51.3 million in H1 FY26, an increase from the US$3.2 million recorded in the prior year period.

Neurizon Therapeutics (ASX:NUZ) commenced dosing for NUZ-001 within the HEALEY ALS platform trial.

Bioxyne (ASX:BXN) announced an upgrade to its FY26 EBITDA guidance, now projected at $16.5–$19 million.

Monash IVF Group (ASX:MVF) has announced its results for the first half of the 2026 financial year, headlined by an underlying net profit after tax of $10.4 million.

Neuren Pharmaceuticals (ASX:NEU) announced strong financial results for the full year 2025, driven by the continued commercial success of DAYBUE.

Ramsay Health Care (ASX:RHC) returns to profit with a $160.7M H1 FY26 result, driven by a surge in Australian hospital performance and a 6.3% dividend increase.